Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report

Jon Salmanton-García1,2, Francesco Marchesi3, Andreas Glenthøj4, Yavuz M. Bilgin5, Jens van Praet6, Julio Dávila-Valls7, Sonia Martín-Pérez7, Jorge Labrador8, Jaap van Doesum9, Iker Falces-Romero10, Francesca Farina11, Martin Schönlein12, Mathilde Chanut13, Verena Petzer11,14, Ildefonso Espigado15, Michelina Dargenio16, Avinash Aujayeb17, Uluhan Sili18, Laura Serrano19, László Imre Pinczés20, Nick de Jonge21, Andrés Soto-Silva22, Caterina Buquicchio23, Lucia Prezioso24, Monia Marchetti25, Stef Meers26, Alessandro Busca27, Paolo Corradini28, Martin Hoenigl29,30, Philipp Koehler1,2, Laman Rahimli1,2, Gökçe Melis Çolak31, Elena Arellano32, Dominik Wolf11,33, Stefanie Gräfe1,2,34, Emanuele Ammatuna9, Caroline Berg Venemyr4, Oliver A. Cornely1,2,35,36, Livio Pagano37,38

[1]  L. Pagano,et al.  Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report , 2022, American journal of hematology.

[2]  M. Hallek,et al.  COVID-19 in patients with hematologic malignancy , 2022, Blood.

[3]  N. Skoetz,et al.  Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review , 2022, Blood Cancer Journal.

[4]  H. Einsele,et al.  Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9) , 2022, Leukemia.

[5]  R. Arbel,et al.  Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years , 2022, Nature Medicine.

[6]  Michael I. Mandel,et al.  Protection by a Fourth Dose of BNT162b2 against Omicron in Israel , 2022, The New England journal of medicine.

[7]  M. Mittelman.  Is COVID vaccine effective in patients with myeloid malignancy? , 2022, British journal of haematology.

[8]  James J. Davis,et al.  Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas , 2022, The American Journal of Pathology.

[9]  L. Pagano,et al.  COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA , 2021, Blood.

[10]  A. Barać,et al.  COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) , 2021, Journal of Hematology & Oncology.

[11]  L. Pagano,et al.  EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19 , 2021, HemaSphere.